THC Therapeutics Inc. (THCT)

[trader993]

http://www.otcmarkets.com/financialReportViewer?symbol=ASUV&id=165347

Effective January 20, 2017, our board of directors and a majority of our shareholders approved the following amendments to our Articles of Incorporation: ? Our total number of authorized shares of common stock has been increased from 90,000,000 shares to 500,000,000 shares.

A change of our corporate name to “THC Therapeutics, Inc.” was approved. The name change, along with a request for a new ticker symbol, will be submitted to FINRA for review prior to becoming effective in the OTC securities markets.

We designated a new class of Series A Preferred Stock. The class of Series A Preferred Stock consists of 3,000,000 shares, par value $0.001 per share. Shares of Series A Preferred Stock are convertible to common stock at a ratio of 100 for 1 and vote together with the common stock on an as-converted basis. Shares of Series A Preferred Stock do not feature any required dividends and rank equally with our common stock on an asconverted basis in the event of liquidation.

Also on January 20, 2017, we entered into an Asset Purchase Agreement (the “Agreement”) with Mr. Romanek. Under the Agreement, we acquired certain patent applications, trademark applications, and web domain names from Mr. Romanek. In exchange, we agreed to issue Mr. Romanek 100,000,000 shares of our common stock and 2,000,000 shares of our newly designated Series A Preferred Stock. Following this transaction,

Mr. Romanek is the beneficial owner of approximately 98.9% of our capital stock on a fully-converted basis and our issued and outstanding common stock will increase to 108,490,391 shares

www.thctherapeutics.com